Back to top
more

Integer Holdings (ITGR)

(Real Time Quote from BATS)

$102.56 USD

102.56
222,229

-0.51 (-0.50%)

Updated Sep 17, 2025 03:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (93 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Insulet Q1 Earnings Top Estimates, Stock Up, 2025 Sales View Raised

by Zacks Equity Research

PODD delivers better-than-expected earnings and revenues in the first quarter of 2025.

Zacks Equity Research

HAE Stock Gains on Q4 Earnings and Revenue Beat, Margins Up

by Zacks Equity Research

Haemonetics' fourth-quarter fiscal 2025 results reflect the positive impact of its long-term plan, with meaningful earnings growth and margin expansion.

Zacks Equity Research

GMED Q1 Earnings & Revenues Miss, '25 EPS View Down, Stock Falls

by Zacks Equity Research

GMED's first-quarter 2025 weak performance reflects soft Enabling Technology deal closures.

Zacks Equity Research

Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up

by Zacks Equity Research

VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests in the first quarter of 2025.

Zacks Equity Research

TMDX Stock Gains Post Q1 Earnings & Revenue Beat, Gross Margin Down

by Zacks Equity Research

Increased organ utilization in liver and continued OCS adoption across both liver and heart boosted TransMedics' first-quarter 2025 performance.

Zacks Equity Research

AMN Stock Gains Following Q1 Earnings & Revenue Beat, Margins Down

by Zacks Equity Research

AMN Healthcare's dismal results in all its segments led to a soft overall first-quarter 2025 performance.

Zacks Equity Research

PacBio Stock Down Despite Q1 Earnings & Revenue Beat Estimates

by Zacks Equity Research

Despite strong Service and other revenues, PACB reports soft first-quarter 2025 results partly due to lower Revio system shipments.

Zacks Equity Research

Illumina Q1 Earnings Top Estimates, Revenues Down Y/Y, Stock Dips

by Zacks Equity Research

ILMN delivers better-than-expected earnings and revenues in the first quarter of 2025.

Zacks Equity Research

QuidelOrtho Stock Gains Following Q1 Earnings Beat, Margins Expand

by Zacks Equity Research

Despite solid performances by the Labs and Immunohematology units and EMEA and Other regions, QDEL reports soft overall top-line results in first-quarter 2025.

Zacks Equity Research

INGN Stock Gains Following Q1 Earnings Beat, Revenues Up Y/Y

by Zacks Equity Research

Inogen's overall first-quarter 2025 results continue to gain from higher business-to-business sales.

Zacks Equity Research

XRAY Stock Gains Post Q1 Earnings & Revenue Beat, Gross Margin Down

by Zacks Equity Research

DENTSPLY SIRONA's customer-centric innovation and operational efficiency drive its first-quarter 2025 performance despite global macroeconomic challenges.

Zacks Equity Research

Phibro Q3 Earnings Top Estimates, Stock Up, 2025 EPS Outlook Raised

by Zacks Equity Research

PAHC's third-quarter fiscal 2025 results reflect the strength of the Animal Health segment.

Zacks Equity Research

Bruker Q1 Earnings & Revenues Top Estimates, Stock Up, Margins Crash

by Zacks Equity Research

Bruker delivers better-than-expected earnings and revenues in the first quarter of 2025.

Zacks Equity Research

EYE Q1 Earnings and Revenues Beat, Gross Margin Up, Stock Surges

by Zacks Equity Research

Continued strength in Managed Care aids National Vision's first-quarter 2025 performance.

Zacks Equity Research

QGEN Q1 Earnings and Revenues Top, Operating Margin Expands, Stock Up

by Zacks Equity Research

QGEN's quarterly performance benefits from a resilient portfolio in the first quarter of 2025.

Zacks Equity Research

AVNS Stock Gains Post Q1 Earnings & Revenue Beat, Gross Margin Down

by Zacks Equity Research

Strength in Avanos' SNS segment drives its first-quarter 2025 performance despite global macroeconomic challenges.

Zacks Equity Research

FMS Stock Up as Q1 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Fresenius Medical's first-quarter results showcase a strong segmental performance, along with reiterating its 2025 outlook for revenue growth.

Zacks Equity Research

CLOV Stock Rises as Q1 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Clover Health's first-quarter 2025 results continue to benefit from the strength of its strong member retention. A decline in operating loss bodes well.

Zacks Equity Research

MASI Stock Slips Despite Q1 Earnings and Revenue Beat, Margins Expand

by Zacks Equity Research

Masimo's first-quarter 2025 results continue to benefit from the strength in its Healthcare businesses despite tariff-related uncertainties.

Zacks Equity Research

Bio-Techne Q3 Earnings & Revenues Top Estimates, Stock Up in Premarket

by Zacks Equity Research

TECH registers continued growth momentum across its Diagnostics & Spatial Biology segment in third-quarter fiscal 2025.

Zacks Equity Research

CRL Q1 Earnings & Revenues Beat Estimates, Stock Rises, '25 View Up

by Zacks Equity Research

Charles River delivers better-than-expected earnings and revenues in the first quarter of 2025.

Zacks Equity Research

MYGN Q1 Earnings Top Estimates, Stock Down on Weak 2025 Outlook

by Zacks Equity Research

Myriad Genetics delivers a narrower-than-expected loss in the first quarter of 2025.

Zacks Equity Research

HIMS Stock Dips Pre-Market Despite Q1 Earnings Beat, Gross Margin Down

by Zacks Equity Research

Hims & Hers' first-quarter 2025 performance reflects continued strength in its online revenue channel on the back of solid product demand and an increasing subscriber base.

Zacks Equity Research

INSP Stock Gains Following Q1 Earnings Beat, Gross Margin Contracts

by Zacks Equity Research

Inspire Medical's first-quarter 2025 performance reflects increased market penetration in existing centers and expansion into new territories and centers, along with strong domestic results.

Zacks Equity Research

ITGR or SONVY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ITGR vs. SONVY: Which Stock Is the Better Value Option?